Tafolecimab

托莱西单抗

Report date: 2026/04/21 20:00:18

Base Information

Drug NameTafolecimab
Drug Alias Name重组全人源抗前蛋白转化酶枯草溶菌素9（PCSK-9）单克隆抗体注射液抗PCSK9单克隆抗体注射液信必乐IBI-306
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProprotein convertase subtilisin kexin type 9 inhibitors
TargetsProprotein convertase subtilisin kexin type 9
Therapy Area/IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[6] 
Global Approved IndicationsHypercholesterolemiaDyslipidemias
Approved Indications in ChinaHypercholesterolemiaDyslipidemias
Original Approved Country/TerritoryMainland China
Original Approved Date2023/08/15
Country/TerritoryMacauMainland China
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesInnovent Biologics(Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesThe First Affiliated Hospital Of Beijing UniversityInnovent Biologics IncBeijing Hospital +[8] 
Inactive CompaniesN/A
Active IndicationsHeterozygous familial hypercholesterolemiaHomozygous familial hypercholesterolemiaHypercholesterolemia +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBank